Gordon Parry

Dr. Parry has over 25 years experience in oncology drug development in early stage biotechnology and mid stage pharmaceutical companies. He began his biotechnology career leading the commercial development of the first GM-CSF based autologous tumor cell vaccines at Somatix Gene Therapy. Upon acquisition of the company by Cell Genesys he moved to Berlex Biosciences, (R&D arm of Schering A.G.), where he became Head of the Cancer Research Department. Subsequent to Berlex Biosciences, he was Vice President of Oncology at Monogram Biosciences. He has served on several advisory councils, including the California Breast Cancer Council and is the author of more than 50 papers and holds several patents. Dr. Parry obtained his PhD in biochemistry at University College London and carried out post-doctoral studies at the University of California, Berkeley, after which he spent 10 years at the Lawrence Berkeley Laboratory.